Research programme: nitric oxide synthase modulators - Apex BioscienceAlternative Names: Nitric oxide synthase modulators research programme - Apex Bioscience
Latest Information Update: 22 Dec 2000
At a glance
- Originator Curacyte Inc
- Class Small molecules
- Mechanism of Action Nitric oxide synthase inhibitors; Nitric oxide synthase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders; Cardiovascular disorders; CNS disorders
Most Recent Events
- 22 Dec 2000 Discontinued-Preclinical for CNS disorders in USA (Unknown route)
- 22 Dec 2000 Discontinued-Preclinical for Cardiovascular disorders in USA (Unknown route)
- 22 Dec 2000 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)